According to a recent study that was conducted by researchers at the Department of Clinical Epidemiology at Aarhus University Hospital in Arhus, Denmark, AF patients who suffer from strokes and are taking anticoagulant medications experienced less severe strokes. The study also showed that those patients experienced shorter hospital stays and lower 30-day mortality rates compared to patients that weren’t taking anticoagulants.
Dr. Sren Johnsen, MD, PhD, from the Department of Clinical Epidemiology at Aarhus University Hospital in Aarhus, Denmark, stated that while AF continues to be a major risk factor for patients suffering from strokes, anticoagulant medications seems to provide the patients with an effective prophylaxis to prevent the strokes. The results of this study were presented at the 8th World Stroke Congress (WSC).
Strokes continue to be a concern for patients with atrial fibrillation. AF is generally treated with prescription anticoagulant drugs like Multaq. While Multaq is an anticoagulant that is specifically designed to lower stroke risks in AF patients, the drug has been linked to serious side effects — liver failure, worsening of the heart condition, lung disease and pulmonary toxicity — that has rendered Multaq unsafe for use. Warfarin is the most popular anticoagulant being used, but apaxiban and dabigatran are quickly gaining on it. These medications have surpassed Multaq as the go-to drugs for stroke prevention in AF patients. While all anticoagulants have been said to cause major bleeding, the dabigatran and apixaban have been viewed as safer and more effective alternatives to the warfarin. Multaq, on the other hand, is just one step away from being recalled indefinitely.
If you or a loved one has suffered from liver failure, a worsening of the heart condition, lung disease or pulmonary toxicity after taking Multaq, contact attorney Greg Jones for a free consultation today. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.